Single Ascending Dose Tolerability Study of DG3173

Trial Profile

Single Ascending Dose Tolerability Study of DG3173

Phase of Trial: Phase I

Latest Information Update: 22 Aug 2014

At a glance

  • Drugs Veldoreotide (Primary)
  • Indications Acromegaly; Carcinoid tumour; Diabetic retinopathy
  • Focus Adverse reactions
  • Sponsors Aspireo Pharmaceuticals
  • Most Recent Events

    • 26 Feb 2009 Results reported in a DeveloGen media release.
    • 17 Oct 2008 New trial record.
    • 10 Oct 2008 Final results were expected in November 2008 according to a DeveloGen media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top